Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98. https://doi.org/10.1038/nrendo.2017.151.

Article  PubMed  Google Scholar 

Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441–50. https://doi.org/10.1161/circulationaha.115.018912.

Article  PubMed  PubMed Central  Google Scholar 

Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18(11):785–802. https://doi.org/10.1038/s41569-021-00559-8.

Article  PubMed  PubMed Central  Google Scholar 

Yamazaki D, Hitomi H, Nishiyama A. Hypertension with diabetes mellitus complications. Hypertens Res. 2018;41(3):147–56. https://doi.org/10.1038/s41440-017-0008-y.

Article  PubMed  Google Scholar 

Kotseva K, De Backer G, De Bacquer D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26(8):824–35. https://doi.org/10.1177/2047487318825350.

Article  PubMed  Google Scholar 

Weinberger MH. Mechanisms of diuretic effects on carbohydrate tolerance, insulin sensitivity and lipid levels. Eur Heart J. 1992;13 Suppl G:5–9. https://doi.org/10.1093/eurheartj/13.suppl_g.5.

Cooper-DeHoff RM, Pacanowski MA, Pepine CJ. Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum. J Am Coll Cardiol. 2009;53(5 Suppl):S28-34. https://doi.org/10.1016/j.jacc.2008.10.037.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Katsi V, Skalis G, Pavlidis AN, et al. Angiotensin receptor neprilysin inhibitor LCZ696: a novel targeted therapy for arterial hypertension? Eur Heart J Cardiovasc Pharmacother. 2015;1(4):260–4. https://doi.org/10.1093/ehjcvp/pvv031.

Article  CAS  PubMed  Google Scholar 

McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. https://doi.org/10.1056/NEJMoa1409077.

Article  CAS  PubMed  Google Scholar 

Cheung DG, Aizenberg D, Gorbunov V, et al. Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: a randomized, double-blind, 8-week study. J Clin Hypertens (Greenwich). 2018;20(1):150–8. https://doi.org/10.1111/jch.13153.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huo Y, Li W, Webb R, et al. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: a randomized, double-blind, 8-week study. J Clin Hypertens (Greenwich). 2019;21(1):67–76. https://doi.org/10.1111/jch.13437.

Article  CAS  PubMed  Google Scholar 

Seferovic JP, Claggett B, Seidelmann SB, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017;5(5):333–40. https://doi.org/10.1016/s2213-8587(17)30087-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Armentaro G, D’Arrigo G, Miceli S, et al. Long term metabolic effects of sacubitril/valsartan in non-diabetic and diabetic patients with heart failure reduced ejection fraction: a real life study. Front Physiol. 2022;13:897109. https://doi.org/10.3389/fphys.2022.897109.

Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2018;71(19):e127-248. https://doi.org/10.1016/j.jacc.2017.11.006.

Article  PubMed  Google Scholar 

Schmieder RE, Wagner F, Mayr M, et al. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. Eur Heart J. 2017;38(44):3308–17. https://doi.org/10.1093/eurheartj/ehx525.

Article  CAS  PubMed  Google Scholar 

Kario K. The sacubitril/valsartan, a first-in-class, angiotensin receptor neprilysin inhibitor (ARNI): potential uses in hypertension, heart failure, and beyond. Curr Cardiol Rep. 2018;20(1):5. https://doi.org/10.1007/s11886-018-0944-4.

Article  PubMed  Google Scholar 

Seki T, Goto K, Kansui Y, et al. Angiotensin II receptor-neprilysin inhibitor sacubitril/valsartan improves endothelial dysfunction in spontaneously hypertensive rats. J Am Heart Assoc. 2017;6(10):e006617. https://doi.org/10.1161/jaha.117.006617.

Geng Q, Yan R, Wang Z, Hou F. Effects of LCZ696 (Sacubitril/Valsartan) on blood pressure in patients with hypertension: a meta-analysis of randomized controlled trials. Cardiology. 2020;145(9):589–98. https://doi.org/10.1159/000507327.

Article  CAS  PubMed  Google Scholar 

Supasyndh O, Sun N, Kario K, Hafeez K, Zhang J. Long-term (52-week) safety and efficacy of Sacubitril/valsartan in Asian patients with hypertension. Hypertens Res. 2017;40(5):472–6. https://doi.org/10.1038/hr.2016.151.

Article  CAS  PubMed  Google Scholar 

Rakugi H, Kario K, Yamaguchi M, et al. Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study. Hypertens Res. 2022;45(5):824–33. https://doi.org/10.1038/s41440-021-00819-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pereira GME, Duarte GS, Katerenchuk V, et al. Safety and tolerability of sacubitril-valsartan: a systematic review and meta-analysis. Expert Opin Drug Saf. 2021;20(5):577–88. https://doi.org/10.1080/14740338.2021.1877658.

Article  Google Scholar 

Li Q, Li L, Wang F, et al. Effect and safety of LCZ696 in the treatment of hypertension: a meta-analysis of 9 RCT studies. Medicine (Baltimore). 2019;98(28):e16093. https://doi.org/10.1097/md.0000000000016093.

Chua SK, Lai WT, Chen LC, Hung HF. The antihypertensive effects and safety of lcz696 in patients with hypertension: a systemic review and meta-analysis of randomized controlled trials. J Clin Med. 2021;10(13):2824. https://doi.org/10.3390/jcm10132824.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–67. https://doi.org/10.1016/s0140-6736(15)01225-8.

Article  PubMed  Google Scholar 

Eid S, Sas KM, Abcouwer SF, et al. New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism. Diabetologia. 2019;62(9):1539–49. https://doi.org/10.1007/s00125-019-4959-1.

Article  PubMed  PubMed Central  Google Scholar 

Oparil S, Acelajado MC, Bakris GL, et al. Hypertension Nat Rev Dis Primers. 2018;4:18014. https://doi.org/10.1038/nrdp.2018.14.

Article  PubMed  Google Scholar 

Luther JM, Brown NJ. The renin-angiotensin-aldosterone system and glucose homeostasis. Trends Pharmacol Sci. 2011;32(12):734–9. https://doi.org/10.1016/j.tips.2011.07.006.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oktay AA, Akturk HK, Jahangir E. Diabetes mellitus and hypertension: a dual threat. Curr Opin Cardiol. 2016;31(4):402–9. https://doi.org/10.1097/hco.0000000000000297.

Article  PubMed  Google Scholar 

Henriksen EJ, Prasannarong M. The role of the renin-angiotensin system in the development of insulin resistance in skeletal muscle. Mol Cell Endocrinol. 2013;378(1–2):15–22. https://doi.org/10.1016/j.mce.2012.04.011.

Article  CAS  PubMed  Google Scholar 

Seferovic JP, Solomon SD, Seely EW. Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control. Ther Adv Endocrinol Metab. 2020;11:2042018820970444. https://doi.org/10.1177/2042018820970444.

Engeli S, Stinkens R, Heise T, et al. Effect of sacubitril/valsartan on exercise-induced lipid metabolism in patients with obesity and hypertension. Hypertension. 2018;71(1):70–7. https://doi.org/10.1161/hypertensionaha.117.10224.

Article  CAS  PubMed  Google Scholar 

Barman HA, Tanyolaç S, Dogan O, et al. Impact of sacubitril/valsartan on lipid parameters in patients with heart failure with reduced ejection fraction. Clin Drug Investig. 2022;42(6):533–40. https://doi.org/10.1007/s40261-022-01161-7.

Article  CAS  PubMed  Google Scholar